Orientin

Orientin is a C-glycosyl flavone found naturally in passion flower, bamboo leaves, and vitex, recognized for its modulation of MAPK signaling pathways and pro-inflammatory cytokine suppression. Preclinical research highlights its roles in nociception, neuroprotection, and pulmonary inflammation, though human clinical trials remain limited.

Origin & History

Orientin is a C-glycosyl flavonoid (luteolin-8-C-glucoside) belonging to the flavone C-glycosides class. It occurs naturally in various medicinal plants, particularly Trollius chinensis Bunge, and is extracted through techniques used in pharmacokinetic studies of plant sources.

Historical & Cultural Context

While orientin itself lacks specific traditional documentation, it is a key compound in Trollius chinensis Bunge, used in traditional Chinese medicine. Its presence in various medicinal plants suggests historical context in plant-based remedies.

Health Benefits

• May reduce pain and cognitive impairment: Mouse studies (14-21 mg/kg) showed increased pain thresholds and improved memory via MAPK signaling modulation (preliminary evidence)
• Potential anti-inflammatory effects: Animal models demonstrated reduced lung injury and cytokine suppression through PFKL targeting and NLRP3/NF-κB inhibition (preliminary evidence)
• May protect vascular health: In vitro and mouse studies showed reduced inflammation and oxidative stress in high glucose conditions (preliminary evidence)
• Possible anti-cancer properties: Preclinical research indicated reduced tumor growth and angiogenesis in colorectal cancer models via HIF1α targeting (preliminary evidence)
• Could improve sepsis outcomes: Mouse endotoxemia studies showed improved survival and reduced lung injury (preliminary evidence)

How It Works

Orientin modulates the mitogen-activated protein kinase (MAPK) signaling cascade, including ERK1/2, JNK, and p38 pathways, which regulate neuronal pain processing and memory consolidation. It suppresses pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, partly through inhibition of phosphofructokinase (PFK) activity and NF-κB transcriptional activation. Additionally, orientin exhibits antioxidant activity by scavenging reactive oxygen species (ROS) and upregulating Nrf2-mediated cytoprotective gene expression.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on orientin. All available evidence comes from preclinical animal and cell culture studies, including research on neonatal pain (PMC10691896), sepsis (PMID: 41548767), acute lung injury (PMID: 33214095), vascular inflammation (PMID: 24950780), and cancer (PMID: 40045186).

Clinical Summary

Current evidence for orientin is derived almost entirely from in vitro cell studies and rodent models, with no robust human randomized controlled trials published to date. Mouse studies using oral or intraperitoneal doses of 14–21 mg/kg demonstrated statistically significant increases in pain thresholds and improvements in maze-based memory tasks, attributed to MAPK pathway modulation. Separate animal models of acute lung injury showed reduced neutrophil infiltration and lower bronchoalveolar lavage concentrations of TNF-α and IL-6 following orientin administration. The translational relevance of these findings to human physiology remains uncertain, and appropriate human dosing has not been established.

Nutritional Profile

Orientin is a C-glycosylated flavone (luteolin-8-C-glucoside) with molecular weight of 448.38 g/mol, not a macronutrient source. It is a bioactive polyphenolic compound found in passion flower (Passiflora sp.), buckwheat, millet, and tulsi leaves at concentrations typically ranging 0.1–2.5 mg/g dry weight depending on plant source. As a pure compound, it contains no protein, fat, or fiber. Bioavailability is notably limited due to its C-glycoside structure — unlike O-glycosides, the C-C bond resists hydrolysis by intestinal enzymes, resulting in partial colonic microbial metabolism into luteolin and other aglycone derivatives. Oral bioavailability is estimated at 5–15% in animal models, with peak plasma concentrations reached at approximately 2–4 hours post-ingestion. Lipid co-administration and nanoparticle encapsulation have been shown to enhance absorption by 2–3 fold in preclinical studies. No clinically established micronutrient content applies to isolated orientin supplementation.

Preparation & Dosage

No clinically studied human dosages exist. Animal studies used 14-21 mg/kg intraperitoneally in mice for pain relief over 6 days. Human dosing cannot be extrapolated from animal data. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Orientin pairs well with Vitexin (also a C-glycosylated flavone from passion flower), as both compounds share complementary NLRP3 inflammasome and NF-κB inhibitory pathways, producing additive anti-inflammatory effects observed in combined animal models. Piperine (5–10 mg) from black pepper is a practical synergist, as it inhibits glucuronidation and CYP3A4/P-glycoprotein-mediated efflux, improving orientin's limited oral bioavailability by up to 2-fold through shared mechanisms demonstrated with structurally similar flavones. Quercetin complements orientin via parallel MAPK signaling modulation and Nrf2/HO-1 antioxidant pathway activation, with quercetin's superior oral bioavailability potentially compensating for orientin's absorption limitations while both target overlapping neuroinflammatory and vascular protection mechanisms.

Safety & Interactions

Orientin has not been evaluated for safety in controlled human clinical trials, making a definitive side effect and interaction profile impossible to establish at this time. Animal studies at pharmacological doses have not prominently reported hepatotoxicity or acute organ toxicity, but chronic toxicity data are lacking. Due to its demonstrated inhibition of NF-κB and cytokine pathways, orientin may theoretically potentiate the effects of immunosuppressant drugs or NSAIDs, warranting caution in individuals on these medications. Pregnant and breastfeeding individuals should avoid orientin supplements given the complete absence of human safety data in these populations.